Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tMageA1-ASC
- Development stage
- Preclinical
- Lead developer
- Vaccizone
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
tMageA1-ASC is a preclinical protein subunit vaccine developed by Vaccizone for the treatment of melanoma. It utilizes the company's proprietary ASC-Speck technology, which involves fusing a truncated version of the melanoma-associated antigen MAGE-A1 (tMageA1) to the ASC (Apoptosis-associated speck-like protein containing a CARD) protein. ASC naturally forms large, highly stable protein aggregates known as "specks" that act as potent inflammasome activators. By presenting the MAGE-A1 antigen on these ASC specks, the vaccine aims to enhance antigen uptake by dendritic cells and trigger a robust T-cell mediated immune response against MAGE-A1-expressing tumor cells.
- Other names
- ASC-MAGE-A1ASC-MAGE-A-1ASC-MAGE-A 1Melanoma vaccineMAGE-A1-ASC speck fusion proteinMAGE-A-1-ASC speck fusion proteinMAGE-A 1-ASC speck fusion protein
02
Targets
PYCARD (Apoptosis-associated speck-like protein containing a CARD)Melanoma-associated antigen 1-specific T cell receptor
Beyond the preview
Go deeper on tMageA1-ASC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tMageA1-ASC.